Cancer Chemotherapy Regimen for Ovarian Cancer
PAC-HF ovarian(120) _________________________________________________________________ adriamycin...... 70 mg/sqm IV on days(weeks) 1(0), 22(3), 43(6), 211(30), 232(33), and 253(36). cisplatin....... 100 mg/sqm IV in 6 l normal saline over 24 h on same days as adriamycin above. cytoxan......... 100 mg/sqm/day orally for 14 days beginning on days(weeks) 64(9), 92(13), 120(17), 148(21), 176(25), and 204(29). hexamethylmelami 150 mg/sqm/day orally for 14 days on same days as cytoxan above. fluorouracil.... 600 mg/sqm IV on the same days specified for cytoxan above. FREQUENCY....... Specified above. reference... Griffin TW. Hunter RA. Cederbaum AI. Tak WK. Ward AD. Schwartz JH. Halpin TF. Strauss GM. Meyer RN. Liepman MK. et al. Treatment of advanced ovarian cancer with sequential combination chemotherapy. Cancer. 60(9):2150-5, 1987 Nov 1. abstract... Fifty previously untreated patients with advanced or recurrent ovarian cancer (FIGO Stages III and IV) were treated with alternating combination chemotherapy. This consisted of high-dose doxorubicin (70 mg/m2) and cisplatin (100 mg/m2) alternated with CHF (cyclophosphamide, hexamethylmelamine, and 5-fluorouracil). Toxicity (myelosuppression, nephropathy, and neuropathy) was infrequent and mild. Clinical response rates were high (94% response, 62% complete clinical response), but the majority of patients had residual intraabdominal disease at second-look surgery (75%). Thirteen patients (26%) are alive after 4 years of observation (minimum follow-up). Survival was adversely influenced in patients who were older than 70, had Stage IV disease, residual tumor bulk greater than 2 cm, and who failed to achieve complete clinical remission. The median duration of survival (28 months) and percentage of long-term survivors appear similar to that in other platinum-based chemotherapy studies. Although the role of alternating combination chemotherapy in epithelial ovarian cancer remains undefined, it is likely that an alternate approach will be necessary to markedly improve survival rates for patients with this disease.
Are you a Doctor, Pharmacist, PA or a Nurse?
Join the Doctors Lounge online medical community
Editorial activities: Publish, peer review, edit online articles.
Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.